No Impact of Hepatitis C Virus Infection on Mortality Among Drug Users During the First Decade After Seroconversion

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 9, 2011, Pages

  Grady, Bart ^a,b   van den Berg, Charlotte ^a,b   van der Helm, Jannie ^a,b   Schinkel, Janke ^b   Coutinho, Roel ^a,b,c   Krol, Anneke ^a   Prins, Maria ^a,b  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Cause Specific Mortality; Community Acquired; Liver Disease; Substance Abuse

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ANTIRETROVIRUS AGENT; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG ABUSE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SEROCONVERSION; SURVIVAL TIME; VIRAL CLEARANCE;

EID: 80052030921     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.05.012     Document Type: Article

References (32)

1. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006, 13:34-41.
2. Kamal S.M. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008, 103:1283-1297.
3. Fu B., Tom B.D., Delahooke T., et al. Event-biased referral can distort estimation of hepatitis C virus progression rate to cirrhosis, and of prognostic influences. J Clin Epidemiol 2007, 60:1140-1148.
4. Freeman A.J., Law M.G., Kaldor J.M., et al. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003, 10:285-293.
5. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000, 20:17-35.
6. Seeff L.B. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009, 29(Suppl 1):89-99.
7. Barrett S., Goh J., Coughlan B., et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001, 49:423-430.
8. Wiese M., Grüngreiff K., Güthoff W., et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany: a 25-year multicenter study. J Hepatol 2005, 43:590-598.
9. Levine R.A., Sanderson S.O., Ploutz-Snyder R., et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 2006, 4:1271-1277.
10. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997, 112:463-472.
11. Seeff L.B., Hollinger F.B., Alter H.J., et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001, 33:455-463.
12. Kamitsukasa H., Harada H., Tanaka H., et al. Late liver-related mortality from complications of transfusion-acquired hepatitis C. Hepatology 2005, 41:819-825.
13. Amin J., Law M.G., Bartlett M., et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006, 368:938-945.
14. Cox A.L., Netski D.M., Mosbruger T., et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005, 40:951-958.
15. Grebely J., Raffa J.D., Lai C., et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat 2011, 18:32-41.
16. Smit C., van den Berg C., Geskus R., et al. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008, 47:221-225.
17. Omland L.H., Krarup H., Jepsen P., et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010, 53:36-42.
18. Omland L.H., Jepsen P., Weis N., et al. Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study. J Viral Hepat 2010, 17:261-268.
19. Memon M.I., Memon M.A. Hepatitis C: an epidemiological review. J Viral Hepat 2002, 9:84-100.
20. Esteban J.I., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008, 48:148-162.
21. van den Hoek J.A., Coutinho R.A., van Haastrecht H.J., et al. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988, 2:55-60.
22. van den Berg C.H., Smit C., Bakker M., et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 2007, 22:183-193.
23. van de Laar T.J., Molenkamp R., van den Berg C., et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepatol 2009, 51:667-674.
24. 2010, SHM, Dutch HIV monitoring foundation, Amsterdam, The Netherlands.
25. Poynard T. Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers. US Patent 6631330. 2003.
26. Rossi E., Adams L., Prins A., et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003, 49:450-454.
27. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: 2009.
28. Neal K.R., Ramsay S., Thomson B.J., et al. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007, 56:1098-1104.
29. Uto H., Stuver S.O., Hayashi K., et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology 2009, 50:393-399.
30. Graham C.S., Baden L.R., Yu E., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562-569.
31. Pugh R.N., Murray-Lyon I.M., Dawson J.L., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-649.
32. Deuffic-Burban S., Wong J.B., Valleron A.J., et al. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004, 40:319-326.